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Background: Hepatocellular carcinoma (HCC) is considered to be one of 
the most aggressive malignancies. Several studies have shown that 
dickkopf-1 (DKK1) is overexpressed in HCC tissue. 
Objective and Methods: The present study aimed at demonstrating the 
diagnostic efficacy of serum levels of DKK1 in HCC in comparison to 
alpha fetoprotein (AFP). Eighty individuals were included in the present 
study, and categorized to three groups: Group I: 40 patients with HCC 
on top of viral liver cirrhosis, Group II: 20 patients with viral induced 
liver cirrhosis without HCC, and Group III: 20 healthy individuals. 
Serum levels of AFP and DKK1 were measured and compared in all 
groups. 
Results: The values of AFP and DKK1 in group I were statistically 
higher than those in groups II and III. At the optimum value of 11.7 
ng/ml, the sensitivity and specificity of serum AFP were 70.0% and 
87.5%, respectively.  DKK1 had higher sensitivity (80.0%) and 
specificity (90.0%) than AFP, at the cut-off value of 1.28 ng/ml for the 
diagnosis of HCC. Area under the curve (AUC) was higher in DKK1 
(0.811) than AFP (0.779) when discriminating between group I and 
other groups. It was noted that the combination of both markers had a 
higher sensitivity and specificity, and a larger AUC than each alone. 
Conclusion: Serum DKK1 is a promising biomarker and is superior to 
AFP for HCC diagnosis. Combination of AFP and DKK1 improved the 
accuracy of HCC diagnosis in relation to each test alone. 
 
                 Copy Right, IJAR, 2019,. All rights reserved. 
…………………………………………………………………………………………………….... 
Introduction:- 
Hepatocellular carcinoma (HCC) represents about 70% to 85% of liver cancer, and is considered to be one of the most 
aggressive malignancies. According to Global Cancer Statistics (GLOBOCAN 2018)
 (1)
, it is the 6
th
 most commonly 
diagnosed cancer and the 4
th
 leading cause of cancer-related deaths in 2018. It is considered the commonest tumor in 13 
geographically diverse countries, including Egypt.
(1) 
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Hepatocellular carcinoma is usually asymptomatic in early stages and most of patients present with non-operable 
disease, and this makes its early diagnosis critical for a good prognosis. So, continuous researches are ongoing to 
find an early sensitive and specific marker for HCC.
(2)
 
 
Alpha fetoprotein is the best studied of all tumor markers and was considered the cornerstone for HCC diagnosis; 
however the American Association for the Study of Liver Diseases (AASLD) does not recommend its use 
anymore.
(3)
 Elevations of AFP levels might be encountered in patients having chronic viral hepatitis, who do not 
have HCC.
(4)
 Meanwhile, about one-third of early-stage HCC patients with small tumor mass have normal AFP 
levels.
(5) 
 
The need for a more sensitive and accurate tool for the detection of HCC had led to the emergence of various tumor 
biomarkers including; Dickkopf1 (DKK1). DKK1 is a secretory protein which is an antagonist of the Wnt/β catenin 
signalling pathway.
(6, 7)
 It is rarely expressed in normal human adult tissues.
(8, 9)
 DKK1 creates a negative feedback 
mechanism to regulate Wnt/β catenin signalling.(10) However, this feedback mechanism is often abolished in cancers 
including HCC.
(11, 12) 
Several studies have shown that DKK1 is overexpressed in HCC tissue, but is not detectable in 
the corresponding non-cancerous liver tissue.
(13, 14)
  
 
Based on these previous studies, the present study hypothesized that serum DKK1 levels are increased in HCC 
patients because of DKK1 overexpression in the HCC tissue. In addition, the present study aimed at demonstrating 
the diagnostic efficacy of serum levels of DKK1 in various stages of HCC in comparison with AFP. 
 
Subjects and Methods:- 
Eighty individuals were included in the present study, and categorized to three groups: 
1. Group I: 40 patients with HCC on top of HCV or HBV induced liver cirrhosis, who were further subdivided 
according to BCLC staging. 
2. Group II: 20 patients with HCV or HBV induced liver cirrhosis without HCC, who were further subdivided 
according to Child Pugh classification.      
3. Group III: 20 healthy individuals with matched age and sex as a control group. 
 
All groups were subjected to history taking and clinical evaluation. Abdominal US was performed for all patients. 
Triphasic CT abdomen was done in case of focal hepatic lesion. Eight milliliters of whole blood were collected from 
all subjects, for complete blood count (CBC), prothrombin time, liver function tests (ALT, AST and albumin), 
kidney function tests (urea, creatinine), viral markers (HCV Ab, HBs Ag), AFP and DKK1 determination. DKK1 
serum levels were measured using ELISA technique. 
 
Data were fed to the computer and analyzed using IBM SPSS software package version 21.0. (Armonk, NY: IBM 
Corp).
(15) 
 
Results:- 
The percentage of males and females was around 70% and 30% in the three groups. The age ranged between 36 and 
74 years with a mean of about 55 years. Group I was almost equally distributed between single liver mass (52.5%), 
and multiple liver masses (47.5%); whether two to three masses (5%) or more than three masses (42.5%). According 
to BCLC classification, stage D was the commonest category (30%), followed by stage C (27.5%), stage B (22.5%), 
and lastly stage A (20%). 
 
Regarding AFP and DKK1 levels, their mean values in group I were higher than those in groups II and III (647.23 
ng/ml and 4.07 ng/ml in group I, 31.75 ng/ml  and 1.03 ng/ml in group II, 3.56 ng/ml  and 0.77 ng/ml in group III, 
respectively). There was a statistically significant difference between group I in comparison to groups II and III, 
while there was no significant difference between groups II and III. 
 
The diagnostic performance of serum AFP and DKK1 levels as markers for the diagnosis of HCC has been 
determined by plotting a receiver-operating characteristic (ROC) curve. At the cut-off value of 11.7 ng/ml, the 
sensitivity of serum AFP in detecting HCC has been estimated to be 70.0%, while its specificity has been shown to 
be 87.5%. DKK1 has higher sensitivity (80.0%) and specificity (90.0%) than AFP, at the cut-off value of 1.28 ng/ml 
for the diagnosis of HCC (Table I). DKK1 has a higher AUC than AFP (0.843 and 0.809, respectively) (Figure I). 
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It is noted from table I and figures 1 & 2 that the combination of both markers has a higher sensitivity and 
specificity, and a larger AUC than each alone. 
 
Table I:-Diagnostic performance for AFP and DKK1 in discriminating HCC cases from other groups (cirrhosis + 
controls) 
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AFP 0.809 <0.001
*
 0.715 0.904 11.70 70.0 87.5 84.8 74.5 
DKK1 0.843 <0.001
*
 0.747 0.940 1.28 80.0 90.0 88.9 81.8 
AFP & DKK1 0.876 <0.001
*
 0.787 0.965  82.50 95.0 93.55 85.55 
 
AUC: Area under the curve -p value: probability value - CI: confidence interval - NPV: negative predictive value -
PPV: positive predictive value -*:Statistically significant at p ≤ 0.05   
 
 
Figure 1:-Diagnostic performance of AFP and DKK1 in discriminating HCC cases from other groups (cirrhosis + 
controls) 
 
 
Figure 2:-Diagnostic performance of combination of AFP and DKK1 in discriminating HCC cases from other 
groups (cirrhosis + controls) 
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Discussion:- 
This study explored the diagnostic efficacy of DKK1 as a biomarker of HCC and was done on 40 HCC patients, 20 
cirrhotic patients, and 20 healthy controls. In this study, serum DKK-1 level was significantly higher in HCC 
patients than those of cirrhotic and healthy groups, while there was no significant difference in DKK1 levels 
between cirrhotic and control groups. This was in accordance with what was stated by many authors 
(16-20)
; as they 
found that DKK1 levels were significantly higher in HCC and could distinguish HCC patients from cirrhotic 
patients and from healthy controls. 
 
In the present study, the optimum diagnostic cut-off value of DKK1 for the diagnosis of HCC was 1.28 ng/ml. This 
agreed with almost all the studies, as seen in table II. On comparing the results of DKK1 and AFP for HCC 
diagnosis, DKK1 had a higher diagnostic performance than AFP. This was also in agreement with other studies 
reviewed, as seen in table II. Testing both DKK1 and AFP increased the diagnostic accuracy of HCC compared with 
either test alone. This combination proved to have a higher sensitivity and specificity, and a larger AUC, and this 
was in line with almost all of the studies reviewed (Table II). 
 
On the other hand, Erdal et al
(16)
 stated that, even though AFP is superior to DKK1 in the diagnosis of HCC, the 
results of the combination were better than those of each marker alone. The exact reason for these different results is 
unclear. This discrepancy may be due to heterogeneity of carcinogenetic mechanisms because of various etiologies 
of chronic liver diseases, different ethnic groups and different number of cases studied.  
 
Table II: Reviewed studies on the diagnosis of HCC, showing the optimum cut-off values for DKK1, diagnostic 
performance of AFP, DKK1 and their combination. 
Study 
(Year) 
DKK1 
optimum cut-
off value 
Markers AUC Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
Our study 
(2018) 
1.28 DKK1 0.843 80.0 90.0 88.9 81.8 
AFP 0.809 70.0 87.50 84.8 74.5 
DKK1 + AFP 0.876 82.5 95.0 93.6 85.6 
Shen et al
(18)
 
(2012) 
2.15 DKK1 0.848 69.1 90.6 89.3 70.6 
AFP 0.830 57.8 88.0 85.1 63.2 
DKK1 + AFP 0.889 73.3 93.4 98.4 86.6 
Kim et al
(17)
 
(2015) 
1.01 DKK1 0.829 89.4 63.1 82.6 75.3 
AFP 0.794 65.0 89.5 89.8 64.3 
DKK1 + AFP 0.901 88.9 76.2 84.3 82.7 
Ge et al
(20)
 
(2015) 
1.31 DKK1 0.889 71.9 88.0 64.0 91.4 
AFP 0.831 79.7 89.4 68.9 93.7 
DKK1 + AFP 0.931 89.9 87.7 68.1 96.4 
Erdal et al
(16)
 
(2016) 
1.40 DKK1 0.726 72.5 61.5 65.9 68.6 
AFP 0.916 77.5 97.4 96.9 80.9 
DKK1 + AFP 0.946 75.0 92.3 92.1 87.8 
 
DKK1 level was elevated in most HCC patients even in those with non-conclusive AFP, and this agreed with Shen 
et al
(18)
, who concluded that DKK1 maintained diagnostic accuracy for HCC patients who were AFP negative. 
Similar to these results, Qin et al
(21)
 concluded that DKK1 can be detected in a subgroup of patients whose AFP 
levels are within the normal range. 
 
This study had its points of strengths and limitations. Its main point of strength was the strict criteria for selecting 
patients in order to remove any confounding factors. The main limitation of the current study was the relatively 
small sample size. 
 
Conclusions:- 
Assessment of serum DKK1 levels could be a useful non-invasive biomarker for the diagnosis of HCC and proved 
to be superior to AFP. The combination of both serum AFP (cut off value of 11.7 ng/ml) and serum DKK1 (cut off 
value of 1.28 ng/ml) improved the diagnostic accuracy of HCC compared with either test alone. 
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